Advertisement for orthosearch.org.uk
Results 1 - 4 of 4
Results per page:
The Bone & Joint Journal
Vol. 102-B, Issue 6 Supple A | Pages 91 - 95
1 Jun 2020
Johnson, Jr. WB Engh, Jr. CA Parks NL Hamilton WG Ho PH Fricka KB

Aims

It has been hypothesized that a unicompartmental knee arthroplasty (UKA) is more likely to be revised than a total knee arthroplasty (TKA) because conversion surgery to a primary TKA is a less complicated procedure. The purpose of this study was to determine if there is a lower threshold for revising a UKA compared with TKA based on Oxford Knee Scores (OKSs) and range of movement (ROM) at the time of revision.

Methods

We retrospectively reviewed 619 aseptic revision cases performed between December 1998 and October 2018. This included 138 UKAs that underwent conversion to TKA and 481 initial TKA revisions. Age, body mass index (BMI), time in situ, OKS, and ROM were available for all patients.


The Bone & Joint Journal
Vol. 102-B, Issue 6 Supple A | Pages 73 - 78
1 Jun 2020
Hamilton WG Gargiulo JM Parks NL

Aims

The purpose of this study was to use pharmacogenetics to determine the frequency of genetic variants in our total knee arthroplasty (TKA) patients that could affect postoperative pain medications. Pharmacogenetic testing evaluates patient DNA to determine if a drug is expected to have a normal clinical effect, heightened effect, or no effect at all on the patient. It also predicts whether patients are likely to experience side effects from medicine. We further sought to determine if changing the multimodal programme based on these results would improve pain control or reduce side effects.

Methods

In this pilot study, buccal samples were collected from 31 primary TKA patients. Pharmacogenetics testing examined genetic variants in genes OPRM1, CYP1A2, CYP2B6, CYP2C19, CYP3A4, CYP2C9, and CYP2D6. These genes affect the pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs and opioids. We examined the frequency of genetic variants to any of the medications we prescribed including celecoxib, hydrocodone, and tramadol. Patients were randomized to one of two groups: the control group received the standard postoperative pain regimen, and the study group received a customized regimen based on the pharmacogenetic results. For the first ten postoperative days, patients recorded pain scores, medication, and side effects.


Orthopaedic Proceedings
Vol. 101-B, Issue SUPP_11 | Pages 3 - 3
1 Oct 2019
Johnson WB Engh CA Hamilton WG Parks NL Ho H Fricka KB
Full Access

Introduction

It has been hypothesized that a unicompartmental knee arthroplasty (UKA) is more likely to be revised than a total knee (TKA) because conversion surgery to a primary TKA is available. The purpose of this study was to determine if there is a lower threshold for UKA revisions compared to TKA revisions based on Oxford Knee Scores and range of motion (ROM).

Methods

We retrospectively reviewed 636 aseptic revision cases performed between 1998 and 2018. This included 137 UKAs that underwent conversion to TKA and 499 TKA revisions. Pre-revision age, body mass index (BMI), time in situ, Oxford Knee Scores, and ROM were available for all patients. T-tests were performed to determine if significant differences existed between the two groups. The minimal clinically important difference (MCID) when comparing Oxford scores between cohorts has been reported as 5 points.


Orthopaedic Proceedings
Vol. 101-B, Issue SUPP_11 | Pages 51 - 51
1 Oct 2019
Hamilton WG Parks NL Gargiulo JM
Full Access

Introduction

Pharmacogenetics evaluates a patient's DNA to determine if a particular drug is expected to have a normal clinical effect, heightened effect, or no effect at all on a patient. It may also predict which patients are most likely to experience side effects from the medications. The purpose of this study was to use pharmacogenetic testing to determine how frequently total knee arthroplasty (TKA) patients have genetic variants to standard postoperative pain medications. We further sought to determine if changing the multimodal program based on these results would improve pain control and reduce side effects.

Methods

In this prospective, randomized study, buccal cheek swab samples were collected from 31 primary TKA patients. Pharmacogenetics testing was performed on the samples to examine genetic variants in genes OPRM1, CYP1A2, CYP2B6, CYP2C19, CYP3A4, CYP2C9, and CYP2D6. These genes affect the pharmacodynamics and pharmacokinetics of NSAIDs and opioids. We examined the frequency of a genetic variant to one of the multimodal medications we prescribe including celecoxib, hydrocodone, and tramadol. Subjects included 9 men and 22 women. Patients were randomized to one of two groups: the control group received the standard postoperative pain regimen; the study group received a customized regimen based on the pharmacogenetic results. For the first 10 postoperative days patients recorded pain scores, amount of pain medication taken, and any side effects experienced.